Failures of Realignment Osteotomy

Manuel F. Schubert(Stanford University), Seth L. Sherman(Stanford University), Alan Getgood(Qatar Orthopaedic and Sports Medicine Hospital), R. Sidhu(Amgen (United States))

Operative Techniques in Sports Medicine

December 28, 2019

10.1016/j.otsm.2019.150714

Cited by 3

Related Papers

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer

|Annals of Oncology|2014|603

Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer

|Annals of Oncology|2013|220

Faecal lactoferrin – a novel test to differentiate between the irritable and inflamed bowel?

|Alimentary Pharmacology & Therapeutics|2010|57

Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)

|Annals of Oncology|2016|46

Low rates of serious complications but high rates of hardware removal after high tibial osteotomy with Tomofix locking plate

|Knee Surgery Sports Traumatology Arthroscopy|2020|42